GlassScriptPhysician profile
Shyla Hossain
NPI 1326788597
$2,882.03
in general payments reported to CMS, 2019-2025
18 companies · $1,837 in 2025
The $1,837 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.51 · 2023: $210 · 2024: $814 · 2025: $1,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,860.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $501.75 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $377.40 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $326.46 | 2024-2025 | Ingrezza |
| Abbvie INC. | $325.82 | 2023-2025 | |
| Corium, LLC | $269.91 | 2024-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $217.86 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $180.50 | 2024-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.73 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $144.13 | 2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $127.51 | 2023-2025 | Auvelity |
| Indivior INC. | $46.79 | 2022-2024 | Perseris |
| Merz Pharmaceuticals, LLC | $40.32 | 2023 | Xeomin |
| Ironshore Pharmaceuticals INC. | $38.95 | 2024 | |
| Vanda Pharmaceuticals INC. | $31.42 | 2025 | Fanapt |
| Alnylam Pharmaceuticals INC. | $23.79 | 2023 | Amvuttra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $19.14 | 2024 | Qelbree |
| Lundbeck LLC | $17.51 | 2024 | Rexulti |
| Ucb, INC. | $16.04 | 2023 | Fintepla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shyla Hossain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.